tiprankstipranks
Advertisement
Advertisement

EXEL Stock Latest News

Recursion Pharmaceuticals announces Vicki Goodman as chief medical officer
The FlyRecursion Pharmaceuticals announces Vicki Goodman as chief medical officer
14d ago
EXEL
RXRX
Exelixis price target lowered to $43 from $46 at RBC Capital
PremiumThe Fly
Exelixis price target lowered to $43 from $46 at RBC Capital
1M ago
MRK
EXEL
Hold Rating on Exelixis Amid Emerging Belzutifan Competition and Uncertain Cabo Revenue Visibility
PremiumRatings
Hold Rating on Exelixis Amid Emerging Belzutifan Competition and Uncertain Cabo Revenue Visibility
1M ago
EXEL
Exelixis: Welireg Competition Tempers RCC Upside but Embedded Cabozantinib Franchise Supports Hold Rating
PremiumRatings
Exelixis: Welireg Competition Tempers RCC Upside but Embedded Cabozantinib Franchise Supports Hold Rating
1M ago
EXEL
Crocs, Linde, Zillow, Exelixis, Qorvo: Insider Cash-Outs
PremiumWeekend Updates
Crocs, Linde, Zillow, Exelixis, Qorvo: Insider Cash-Outs
1M ago
Z
LIN
Exelixis: Solid Financial Beat and Advancing Oncology Pipeline Drive Upgraded Earnings Outlook and $54 Price Target
PremiumRatingsExelixis: Solid Financial Beat and Advancing Oncology Pipeline Drive Upgraded Earnings Outlook and $54 Price Target
2M ago
EXEL
Exelixis price target raised to $54 from $52 at H.C. Wainwright
Premium
The Fly
Exelixis price target raised to $54 from $52 at H.C. Wainwright
2M ago
EXEL
Arcus Biosciences downgraded to Equal Weight from Overweight at Wells Fargo
Premium
The Fly
Arcus Biosciences downgraded to Equal Weight from Overweight at Wells Fargo
2M ago
EXEL
RCUS
Exelixis Earnings Call: CABOMETYX Strength, ZANZA Catalyst
PremiumCompany Announcements
Exelixis Earnings Call: CABOMETYX Strength, ZANZA Catalyst
2M ago
EXEL
Exelixis price target raised to $44 from $43 at Stifel
PremiumThe Fly
Exelixis price target raised to $44 from $43 at Stifel
2M ago
EXEL
Exelixis: Solid Q4 Execution and Advancing Pipeline Underpin Buy Rating and 2026 Earnings Power
PremiumRatings
Exelixis: Solid Q4 Execution and Advancing Pipeline Underpin Buy Rating and 2026 Earnings Power
2M ago
EXEL
Exelixis reports Q4 EPS 94c, consensus 81c
PremiumThe Fly
Exelixis reports Q4 EPS 94c, consensus 81c
2M ago
EXEL
Exelixis sees FY26 revenue $2.525B-$2.625B, consensus $2.6B
PremiumThe FlyExelixis sees FY26 revenue $2.525B-$2.625B, consensus $2.6B
2M ago
EXEL
Exelixis (EXEL) Q4 Earnings Cheat Sheet
Premium
Pre-Earnings
Exelixis (EXEL) Q4 Earnings Cheat Sheet
2M ago
EXEL
Exelixis price target raised to $44 from $41 at Barclays
Premium
The Fly
Exelixis price target raised to $44 from $41 at Barclays
2M ago
EXEL
Exelixis: Advancing Zanzalintinib Pipeline Underpins Buy Rating and $52 Target on Multi-Tumor Commercial Potential
PremiumRatings
Exelixis: Advancing Zanzalintinib Pipeline Underpins Buy Rating and $52 Target on Multi-Tumor Commercial Potential
2M ago
EXEL
Exelixis reports zanzalintinib new drug application accepted for review by FDA
PremiumThe Fly
Exelixis reports zanzalintinib new drug application accepted for review by FDA
2M ago
EXEL
Exelixis price target raised to $49 from $48 at Morgan Stanley
PremiumThe Fly
Exelixis price target raised to $49 from $48 at Morgan Stanley
2M ago
EXEL
Exelixis price target raised to $52 from $49 at H.C. Wainwright
PremiumThe Fly
Exelixis price target raised to $52 from $49 at H.C. Wainwright
2M ago
EXEL
Exelixis price target raised to $51 from $49 at Truist
PremiumThe FlyExelixis price target raised to $51 from $49 at Truist
3M ago
EXEL
Exelixis reports preliminary FY25 revenue $2.32B, consensus $2.33B
Premium
The Fly
Exelixis reports preliminary FY25 revenue $2.32B, consensus $2.33B
3M ago
EXEL
Exelixis sees FY26 revenue $2.525B-$2.625B, consensus $2.62B
Premium
The Fly
Exelixis sees FY26 revenue $2.525B-$2.625B, consensus $2.62B
3M ago
EXEL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >